February 13, 2017
Acacia Pharma’s PONV drug Baremsis meets goals, next step submitting to the FDA
Acacia Pharma Group has made final pivotal Phase 3 study testing amisulpride injection Baremsis, formerly APD421, for patients with post-operative nausea & vomiting (PONV), after getting antiemetic prophylaxis, and now all phases met primary endpoints.